AACR 2012: ABT-199 is a new Bcl-2 inhibitor with potential in Chronic Lymphocytic Leukemia

The New Drugs on the Horizon session at the recent annual American Association for Cancer Research (AACR) meeting in Chicago showcased several drugs that I expect we will be hearing more of in the future. I previously wrote about AZD3514 in prostate cancer.

Another small molecule that particularly impressed me in this AACR session was ABT-199, a potent and selective inhibitor of Bcl-2. Steven Elmore from Abbott Laboratories presented impressive early data from an ongoing phase I trial in patients with chronic lymphocytic leukemia (CLL).

Purchase Access to Premium Content

Click on blue icon to purchase access to all Premium Content. Current subscription rate is $399 for 3 months access or $1200 for 12 months access. Subscriptions do not auto renew. Rates may change without notice and are non-refundable. Please read the Terms of Use before purchasing and if in communications our Guidance to PR Professionals.